MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$15.7M |
| 2 |
Inhibrx, Inc. Common Stock
INBX
|
+$15.1M |
| 3 |
Intellia Therapeutics
NTLA
|
+$7.11M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$3.31M |
| 5 |
Geron
GERN
|
+$3.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$9.43M |
| 2 |
Axsome Therapeutics
AXSM
|
+$4.13M |
| 3 |
Relmada Therapeutics
RLMD
|
+$3.72M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$3.68M |
| 5 |
Cytokinetics
CYTK
|
+$1.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$967M
| $98.1M | 27.24% |
7,648,268
| – | – |
2021 Q1
5 quarters
|
|
2
DELISTED
iTeos Therapeutics
ITOS
| $36M | 9.99% |
1,745,943
| – | – |
2020 Q3
7 quarters
|
|
3
DELISTED
Repare Therapeutics
RPTX
| $22.9M | 6.37% |
1,639,849
| – | – |
2020 Q2
8 quarters
|
|
4
DELISTED
Merus
MRUS
| $20.8M | 5.78% |
919,482
| – | – |
2020 Q2
8 quarters
|
|
|
5
Intellia Therapeutics
NTLA
$1.75B
| $15.5M | 4.3% |
299,409
+140,000
| +88% | +$7.11M |
2021 Q3
3 quarters
|
|
|
6
Iovance Biotherapeutics
IOVA
$3.84B
| $13.2M | 3.68% |
+1,200,000
| New | +$15.7M |
2022 Q2
0 quarters
|
|
|
7
Geron
GERN
$575M
| $13.1M | 3.63% |
8,434,991
+2,285,714
| +37% | +$3.23M |
2021 Q3
3 quarters
|
|
|
8
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $11.6M | 3.23% |
+1,023,325
| New | +$15.1M |
2022 Q2
0 quarters
|
|
|
TCRR
9
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $9.8M | 2.72% |
3,370,982
| – | – |
2019 Q4
10 quarters
|
|
10
Werewolf Therapeutics
HOWL
$47.9M
| $9.8M | 2.71% |
2,388,011
| – | – |
2021 Q2
4 quarters
|
|
|
11
Cytokinetics
CYTK
$8.76B
| $7.63M | 2.12% |
194,246
-30,000
| -13% | -$1.21M |
2021 Q3
3 quarters
|
|
12
DELISTED
Crinetics Pharmaceuticals
CRNX
| $6.84M | 1.9% |
366,676
| – | – |
2021 Q3
3 quarters
|
|
13
BioCryst Pharmaceuticals
BCRX
$2.16B
| $6.76M | 1.88% |
639,089
| – | – |
2021 Q3
3 quarters
|
|
14
Travere Therapeutics
TVTX
$4.75B
| $6.74M | 1.87% |
277,950
| – | – |
2021 Q3
3 quarters
|
|
15
DELISTED
Y-mAbs Therapeutics
YMAB
| $6.71M | 1.86% |
443,702
| – | – |
2019 Q4
10 quarters
|
|
16
Harmony Biosciences
HRMY
$2.26B
| $6.71M | 1.86% |
137,517
| – | – |
2021 Q3
3 quarters
|
|
|
HARP
17
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $6.11M | 1.7% |
319,671
| – | – |
2019 Q4
10 quarters
|
|
18
Mirum Pharmaceuticals
MIRM
$5.52B
| $5.62M | 1.56% |
288,531
| – | – |
2021 Q3
3 quarters
|
|
19
Arcutis Biotherapeutics
ARQT
$4.03B
| $5.51M | 1.53% |
258,500
| – | – |
2022 Q1
1 quarter
|
|
|
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $5.47M | 1.52% |
180,000
| – | – |
2022 Q1
1 quarter
|
|
21
DELISTED
Amicus Therapeutics
FOLD
| $5.32M | 1.48% |
495,603
| – | – |
2021 Q3
3 quarters
|
|
|
EPZM
22
DELISTED
Epizyme, Inc
EPZM
| $5.04M | 1.4% |
3,425,202
| – | – |
2019 Q4
10 quarters
|
|
23
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $4.23M | 1.18% |
856,798
| – | – |
2019 Q4
10 quarters
|
|
24
Verastem
VSTM
$1.18B
| $3.76M | 1.05% |
270,388
| – | – |
2021 Q3
3 quarters
|
|
|
25
Madrigal Pharmaceuticals
MDGL
$9.9B
| $3.22M | 0.89% |
+45,000
| New | +$3.31M |
2022 Q2
0 quarters
|
|
Similar funds
MPM BioImpact's Q2 2022 Portfolio in Review
As of Q2 2022, MPM BioImpact held 41 positions worth $360M, down 3.4% from $373M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
MPM BioImpact deployed $26.7M of net new capital in Q2 2022, opening 4 new positions and adding to 3 existing holdings. Its largest new stake was Iovance Biotherapeutics: 1,200,000 shares worth $13.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Cytokinetics, an estimated $1.21M trimmed.
- MPM BioImpact's largest Q2 2022 buy was Iovance Biotherapeutics: 1,200,000 shares worth $13.2M.
- MPM BioImpact added most to Intellia Therapeutics in Q2 2022, an estimated $7.11M increase.
- MPM BioImpact's biggest Q2 2022 reduction was Cytokinetics, cutting an estimated $1.21M.
- MPM BioImpact fully exited Turning Point Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $9.43M.
- MPM BioImpact's ten largest holdings make up 70% of its $360M portfolio in Q2 2022.
- MPM BioImpact opened 4 new positions and closed 4 in Q2 2022.
- MPM BioImpact's portfolio value fell 3.4% quarter-over-quarter to $360M.
Based on MPM BioImpact's 13F filing for Q2 2022, filed 11 Aug 2022.